Navigating Weight Loss: Can You Take Wegovy Once a Month for Maintenance?

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide's mechanism—slowing stomach emptying and reducing appetite signals—works best when medication levels stay consistent in your bloodstream. Many people wonder if stretching doses to once monthly can maintain their weight loss progress while reducing treatment frequency. Understanding how dosing schedules interact with your metabolism helps you choose the right approach.

How Semaglutide Dosing Affects Weight Loss and Maintenance

Standard semaglutide therapy uses weekly injections because this schedule maintains steady drug levels in your system. Your GLP-1 receptor activation depends on consistent medication exposure; gaps in coverage can trigger appetite rebound and weight regain within days. Research on extended dosing intervals shows that stretching injections beyond one week typically reduces effectiveness compared to weekly administration.

Monthly dosing exists for certain formulations designed with extended-release technology, but compounded semaglutide—the injectable version PlexusDx offers—is not formulated for once-monthly delivery. Instead, PlexusDx provides weekly compounded semaglutide injections that you self-administer at a flat rate at $189/mo month-to-month, or from $149/mo on the 6-month plan, with your dose able to increase without any price change as your provider adjusts your therapy.

If you've already achieved your goal weight and want to reduce injection frequency, talking with your healthcare provider about spacing protocols matters. Some people transition to lower weekly doses rather than monthly injections, maintaining appetite control while simplifying their routine. Your individual response depends on factors like your baseline metabolic rate, genetic predispositions to weight regain, and how your body processes GLP-1 signals.

The Science Behind GLP-1 Receptor Activation and Weight Stability

GLP-1 receptor signaling controls multiple appetite pathways simultaneously—slowing gastric emptying, increasing fullness signals to your brain, and reducing hunger hormone levels. When semaglutide concentration drops too low between doses, these signals weaken, and your appetite naturally rebounds. Studies comparing weekly versus extended-interval GLP-1 therapy show that weekly dosing maintains more stable weight loss outcomes over 12 months.

The PlexusDx Precision Peptide Genetic Test reports on variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Maintenance Versus Active Weight Loss Dosing With Semaglutide

Active weight loss typically requires titrating semaglutide upward over 16–20 weeks, with doses increasing every four weeks until you reach your therapeutic range. During this phase, weekly injections help your body adapt and sustain consistent weight reduction. Once you've stabilized at your goal weight for 4–8 weeks, your provider may discuss maintenance strategies—sometimes using a lower weekly dose instead of stopping completely.

Maintenance therapy differs from stopping treatment entirely; even lower semaglutide doses help prevent rapid weight rebound. Without any GLP-1 medication, most people regain 50–70% of lost weight within one year because appetite hormones return to baseline. A maintenance approach—staying on semaglutide at a reduced dose, still administered weekly—preserves your progress while managing side effects and costs.

PlexusDx's compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan regardless of your dose level, meaning maintenance therapy costs the same as active weight loss treatment. Your dose may increase or decrease based on your clinical response, but your price remains flat—a transparent alternative to traditional dosing ladders tied to pricing tiers.

Personalized GLP-1 Therapy: Beyond Standard Dosing Schedules

Precision medicine recognizes that not everyone's body handles semaglutide identically. Genetic variants in your GLP-1 receptor, FTO gene (rs9939609, which influences hunger and energy expenditure), MC4R pathway (rs17782313, linked to melanocortin-driven appetite control), and GIPR receptor (rs1800437, affecting incretin response) all shape your medication response. PlexusDx's Precision Peptide Genetic Test maps 49 peptides and 14 biological pathways to reveal these individual differences.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Rather than asking whether once-monthly dosing works universally, the better question is: what dosing frequency and dose level does your specific genetics and metabolism require? PlexusDx connects genetic insights to personalized dosing recommendations, helping you avoid trial-and-error and align your treatment with your biology. Adding the Precision Peptide Genetic Test ($298) transforms your maintenance approach from guesswork into data-driven precision.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can I switch to once-monthly semaglutide injections after reaching my goal weight?

PlexusDx's compounded semaglutide is formulated for weekly injection because this dosing schedule maintains stable appetite control. Once-monthly semaglutide exists in certain brand formulations with extended-release technology, but your PlexusDx provider typically recommends weekly dosing to prevent weight rebound. Ask your healthcare provider about tapering to a lower weekly dose during maintenance instead of spacing doses further apart.

What does research show about GLP-1 therapy effectiveness on extended dosing schedules?

Clinical trials comparing weekly versus monthly GLP-1 dosing show that weekly administration produces more consistent appetite suppression and steadier weight loss. Extended intervals allow appetite hormones to spike between injections, potentially triggering cravings and weight regain. Weekly semaglutide maintains GLP-1 receptor activation at therapeutic levels, which is why most providers recommend this schedule for both active weight loss and maintenance.

Does PlexusDx charge differently if I use less semaglutide during maintenance?

No. PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan flat—your dose may increase or decrease as your provider adjusts your therapy, but your price remains the same. This transparent pricing model removes the cost barrier to maintenance therapy, allowing you to sustain your weight loss progress without unexpected price hikes as your clinical needs evolve.

What happens to your weight if you stop semaglutide therapy entirely?

Most people regain 50–70% of their lost weight within 12 months after stopping GLP-1 medication because appetite hormones and hunger signals return to baseline. Maintenance therapy—staying on a lower semaglutide dose indefinitely—prevents this rebound. Your provider can discuss long-term treatment plans that balance your weight stability, side effect tolerance, and treatment costs.

How does genetic testing help me decide on the right semaglutide dosing for maintenance?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.